September 20th, 2012
Why I Applaud the Skeptical Physicians
Joseph S. Ross, MD, MHS
Is skepticism of industry-funded trials warranted even when they are designed, conducted, and reported with the utmost rigor?
March 27th, 2012
Statistical Pitfalls: The Onus is on Us to Look at the Evidence
Jeremiah Depta, MD
Light, not just heat, is generated in a highly animated and entertaining session on how to interpret research data.
January 26th, 2012
Sizing Up Clinical Trials — Quickly and Intuitively
John E Brush, MD
A pharmaceutical sales rep comes to your office bringing lunch. He shows you a graphic stating that Multaq (dronedarone) reduced the primary endpoint in the ATHENA trial by 24%. The fine print shows an impressive P value: <0.0001. You come away satisfied that this drug looks good. You may not realize it, but you also […]
NEJM Journal Watch — Recent Cardiology Articles- Transcatheter Valve Replacement for Severe Tricuspid Regurgitation
- Time in Blood Pressure Target Range and Outcomes in Hypertension: Real-World Data
- When to Start Anticoagulation After Ischemic Stroke in Patients with Atrial Fibrillation
- Aortic-Valve Replacement vs. Clinical Surveillance for Asymptomatic Severe Aortic Stenosis
- Secondary Hypertension in Young Adults